Yes, No, Maybe So

Thanks for participating in The Rundown’s informal poll! Accordingly, 11% of respondents said they would receive a COVID-19 vaccine; we had one undecided… and the remainder said no to the vaccine.

Here’s a sample from each category:

“Yes. My wife and I are closing in on 70-years old. We do not have comorbidities, but we are clearly in the ‘at-risk’ zone for the virus. We want to be able to go out and enjoy life while we are still relatively healthy.

“I think the priority for vaccination should be medical personnel, other first responders, the military and ‘at-risk’ individuals in that order.”

And this from our undecided voter: “My trust level in the government – after watching the comedy of errors called the pandemic response – is at an all-time low. I’m still in limbo about participating.”

Here’s a common refrain — albeit with a creative spin — about being one of the first to take a new vaccine: “Would you have wanted to be on the first Sputnik launch?”

Our final contributor says: “I would personally opt out of a Covid vaccine, if it ever comes out.

“My wife and I both contracted Covid in March. She had a tough time with the fevers (along with second-trimester pregnancy), but with the help of prescription antibiotics she recovered in two weeks. I on the other hand, had only minor symptoms, nothing more. I did not take any medications besides my daily multivitamins.

“So my question is how effective will a new vaccine be? And will the feds mandate it or will they keep it optional. I have never even gotten a flu shot, and don’t plan on doing so.

“Love the work you guys do. I enjoy reading The Rundown.”

Again, thanks to all who wrote in! Another question: Even if you wouldn’t take the vaccine yourself, would you be open to investing in companies developing COVID-19 vaccines?

Send your opinions to,

Your Rundown for Friday, Sept. 18, 2020…

Under-the-Radar Biotech Buyout

With the news dominated by Operation Warp Speed and COVID-19 vaccines, some other news in the biotech sector has been overlooked.

Namely, Gilead Sciences (GILD) has struck an agreement to purchase oncology company Immunomedics, Inc. (IMMU) for about $88 per share or $21 billion.

The deal’s expected to go through near the end of the year, and with the purchase, Gilead will acquire Immunomedics’ FDA-approved Trodelvy for the treatment of metastatic breast cancer. The cancer treatment will fill out Gilead’s stable of oncology treatments.

Gilead’s CEO Daniel O’Day says: “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer.”

According to analyst Michael J. Yee of the Jefferies Group: “Investors may take some time to digest all the deals but these add lots more drivers and clear momentum in oncology and less reliance on HIV. Maintain Buy.

“We are positively biased on the acquisition as this moves Gilead Sciences (GILD) quickly into a commercial footprint… to prepare for other pipeline,” he concludes.

Gilead shares are at $64.86 at the time of writing; Mr. Yee’s price target of $78, however, is in line with other analysts’ estimates at about $79 per share in the next twelve months, with one outlier at $105 per share in the same time.

Watch for more news as the biotech sector steps up.

Market Rundown for Friday, Sept. 18, 2020

S&P 500 futures are up 2 points to 3,360.

Oil’s steady at $41.00 for a barrel of WTI.

Gold’s added $7.29 to its price, currently at $1,957.20 per ounce.

Bitcoin is up $40.75 to $10,968.71.

Send your comments and questions to,

We hope you have a pleasant weekend, and we’ll catch up with you Monday.

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler